Interactive Breakout Discussion Groups
4:10 pm Find Your Table and Meet Your Moderator
4:15 pm Interactive Breakout Discussion Groups
Concurrent breakout discussion groups are interactive, guided discussions hosted by a facilitator or set of co-facilitators to discuss some of the key issues presented earlier in the day’s sessions. Delegates will join a table of interest and become an active part of the discussion at hand. To get the most out of this interactive session and format please come prepared to share examples from your work, vet some ideas with your peers, be a part of group interrogation and problem solving, and, most importantly, participate in active idea sharing.
5:00 - 6:00 pm Welcome Reception in the Exhibit Hall with Poster Viewing
TABLE 1: Creating an Achievable Path to True Interoperability and Continuous Healthcare IT Improvement
Charles Jaffe, M.D., Ph.D., Chief Executive Officer, HL7
Oscar Diaz, Chief Executive Officer, Healthcare Services Platform Consortium (HSPC)
Nick van Terheyden, M.D., Chief Medical Officer, NTT DATA, Inc.
Vivian Singletary, Director, Public Health Informatics Institute, Task Force for Global Health
- What are the goals of the HealthCare Platform Consortium?
- What are the best strategies for achieving these goals?
- What is the technical approach for making interoperability easier?
- What would it take for my organization to adopt standards based services and/or contribute to the evolution of HealthCare IT infrastructure?
TABLE 2: Leveraging Analytics and Dashboards to Promote Population Health Accountability
Donald Levick, M.D., MBA, CMIO, Lehigh Valley Health Network
Michael Sheinberg, M.D., Medical Director, Medical Informatics, Lehigh Valley Health Network
Blackford Middleton, M.D., Chief Informatics & Innovation Officer, Apervita, Inc., Past Chairman of the Board, American Medical Informatics Association (AMIA)
Adrian Zai, M.D., Clinical Director, Population Informatics, Laboratory of Computer Science, Massachusetts General Hospital
Alan Eisman, Senior Vice President, Sales and Business Development, HBI Solutions
- How to interface technology with workflows to drive outcomes
- What are possible organizational structures that support the use of analytics and population health
- What does the evidence say about cloud-based CDS and analytics?
- What cultural, technical and process barriers must be overcome to facilitate sharing of CDS and analytics?
- What is the expected benefit from sharing CDS and analytics?
TABLE 3: Leveraging Social Determinants of Health (SDOH): What Data Do We Need, How Can We Collect It...and Then What Do We do with It?
Joel Reich, M.D., Chief Medical Officer, Eastern Connecticut Health Network
Samuel Nordberg, PhD., Director, Behavioral Health Informatics and Innovation, Atrius Health
Jacob Kagan, M.D., Director, Behavioral Health Specialty, Harvard Vanguard Medical Associates, Atrius Health
Divyes Patel, Manager Information Delivery Innovation, Blue Cross Blue Shield, TN
Mark Hiatt, M.D., MBA, Executive Medical Director, Regence BlueCross BlueShield of Utah
- How to leverage Lifestyle Based Analytics (LBA) and identify and manage social determinants of health (“SDOH”) including housing, food, finances, transportation, personal safety, and environmental hazards in order to improve overall pop health management?
- How to identify patients with underlying behavioral health problems, and to stratify those patients by risk and treatment needs?
- Challenges of integrating Lifestyle Based Analytics (LBA) with traditional clinical markers?
- Behavioral Screening and Intervention (BSI): Improving Quality Metric Performance and Generating Shared Savings
- Ethical Dilemma: Now that we have identified the SDOHs...Do we have the resources to address them?
TABLE 4: Improving Health and Reducing Costs through Traditional and Innovative Approaches to Coordinated Care and Patient Engagement
Adrian Gropper, M.D., CTO, Patient Privacy Rights
Regina Au, Strategic Marketing Consultant, New Product Planning/Marketing, BioMarketing Insight
- At this time, health information management (HIM) professionals are the custodians of patient data. Is it realistic to think that at some point patients/consumers will be able to take on the role as custodians of their data, and if so, what will be necessary to make that a reality?
- What technologies can be used to help coordinate and care and achieve real engagement?
- Care coordination needs to extend to all parts of the continuum. Are the technologies and supporting processes understood well enough to make this a reality? If not, how do we make it so?
- Are the financial models and the incentives properly aligned to encourage coordinated care and ensure patient engagement? If not, what should be done to align them?
TABLE 5: Sensor Design, Engineering & Manufacturing for Integrated Healthcare Devices
Thomas Dawidczyk, Ph.D., Analyst, Lux Research’s Wearable Electronics Intelligence Service
Perena Gouma, Ph.D., Professor, Department of Materials Science and Engineering, University of Texas at Arlington
- What are the most promising emerging technological innovations enabled by next generation sensors?
- What are the key obstacles to future commercialization of life changing medical devices?
- How have materials and advances in nano and micro fabrication techniques led to significant increases in the commercialization of sensors for healthcare applications? Where is there opportunity for collaboration, market entry, innovation?
TABLE 6: Where are the Key Opportunities for Data Sharing and Collaboration between Pharmaceutical Industry, Clinical Research/Trials, Healthcare Providers and Payers?
Jeff James, CEO, Wilmington Health
Jennifer Byrne, Founder, The Greater Gift; Former CEO, PMG Research
Nicole Hobbs, Ph.D., Director, Medical Informatics, Business Development, Intermountain Healthcare
John Cai, MD, PhD, Director Medical Informatics, Information and Knowledge Utilization (IKU), Celgene
- Where are the most immediate value-propositions for patients and ACOs to work with pharma on collaborations to develop novel solutions?
- What are the ways in which pharma solutions like patient support programs, adherence programs, and mobile health tools are being integrated into larger healthcare ecosystems?
- How can Healthcare benefit from more engagement with Pharma and how can Pharma support Healthcare to improve patient outcomes?
TABLE 7: Clinical Trials of the Future: Big Data, Infrastructure, and Interoperability
Nirmal Keshava, Ph.D., Senior Principal Informatics Scientist, R&D Information, AstraZeneca
Katherine Vandebelt, Global Head, Clinical Innovation, Eli Lilly and Company
Rebecca Kush, Ph.D., President and Founder, CDISC
- What do clinical trials look like in the future in terms of data collection, analysis, and sharing across stakeholders?
- Where are the opportunities to collect, analyze, and use big data before, during, or after clinical trials?
- What is needed from an infrastructure and interoperability standpoint to enable data-driven clinical trials in collaboration with healthcare?
TABLE 8: The Business of Telemedicine: How the Internet of Things is Driving Change in Healthcare
Nick Assad, Senior Director, Business Development, Rally Health Inc.
Adam Licurse, MD, Associate Medical Director, Primary Care, BWH Physicians Organization, Partners Center for Population Health
- Providing value to the clinician and the patient with telemedicine, in light of the economic realities of current and future reimbursement and compensation models
- High value telehealth uses, approach to payer reimbursement, internal compensation, clinical adoption, and patient engagement
- How value-based virtual health will play a critical role in the success of healthcare's transition
TABLE 9: Multi-parameter Passive Monitoring and Data Analysis for Clinical Decisions, Outside of the Clinic
Christopher Hartshorn, Ph.D., Program Director, Center for Strategic Scientific Initiatives, National Cancer Institute, NIH
- What target clinical areas will passive, continuous monitoring from wearable devices be most useful?
- What emerging wearable devices/sensors will be most useful to couple with current consumer devices, in order to develop more clinically useful decision making tools from multi-device/sensor signatures? What clinical areas would these be more beneficial? What other areas would they be useful to understanding the subtleties of disease versus health?
- How could these benefit patients of clinical trial cohorts with respect to precision medicine? What secondary endpoints could be coupled to these trials with a corresponding passive monitoring device?
- In theory, to utilize for clinical decision making, one would prefer data from multiple devices/sensors outside of the clinic. What would this look like from a data perspective? Data aggregation, integration, and algorithms performed on user device or with onsite servers? Standards and regulatory issues? How would this look like from an ‘Internet-of-things’ perspective while maintaining HIPAA compliance?